Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
SSY Group ( (HK:2005) ) has shared an update.
SSY Group Limited has received approval from the National Medical Products Administration of China for the production and registration of several drugs, including Aminophylline Tablets, Procaterol Hydrochloride Inhalation Solution, and Ademetionine 1,4-Butanedisulfonate for Injection. These approvals signify the company’s progress in expanding its product offerings in the treatment of respiratory and liver conditions, potentially enhancing its market position and providing new treatment options for patients.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company is involved in creating medications primarily for respiratory and liver-related conditions, with a market focus on China.
YTD Price Performance: -14.68%
Average Trading Volume: 14,047,167
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.56B
For an in-depth examination of 2005 stock, go to TipRanks’ Overview page.